ClinicaliQ Trial Snapshot
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer — Recruiting • Phase II • Oncology • NCT06820463.
- What is being tested: Telisotuzumab adizutecan (a novel targeted therapy) combined with standard chemotherapy (oxaliplatin, fluorouracil, folinic acid), bevacizumab, and panitumumab in metastatic colorectal cancer; evaluating both safety profile and efficacy outcomes.
- Patient eligibility overview: Adult participants with metastatic colorectal cancer; specific eligibility criteria regarding prior treatment history, performance status, and organ function would be detailed in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing…
Eligibility Snapshot
- : * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Laboratory values meeting the criteria within the protocol. * Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.